Lawrence D. Ginsberg, MD

Lawrence D. Ginsberg, M.D., is a seasoned psychiatrist with over four decades of experience in the field. He is the founder and CEO of Red Oak Psychiatry Associates, P.A., one of Houston's largest mental health practices, established in 1991. Dr. Ginsberg specializes in treating a wide range of psychiatric conditions, including mood disorders, anxiety disorders, schizophrenia, autism, PTSD, and ADHD, providing care to patients of all ages, starting from three years old.

Throughout his career, Dr. Ginsberg has been deeply involved in psychiatric clinical research, serving as a principal investigator in over 200 clinical trials. His expertise in psychopharmacology has led him to lecture frequently for various pharmaceutical companies on related topics. He has also contributed extensively to the academic community with over 100 publications, including journal articles, abstracts, and monographs.

In addition to his clinical and research endeavors, Dr. Ginsberg is an active member of the editorial board of two medical journals. His commitment to advancing the field of psychiatry is evident through his extensive work in both patient care and academic contributions, reflecting a lifelong dedication to improving mental health outcomes.

• B.S. in Chemistry, magna cum laude - University of Miami
• MD-University of Miami School of Medicine

• Diplomat American Board of Addiction Medicine

• Life Fellow Amercian Society for Adolescent Psychiatry,
• Fellow American Society of Addiction Medicine, Fellow American Society of Clinical Psychopharmacology

• American Medical Association
• American Psychiatric Association
• American Academy of Psychiatry and the Law
• American Society of Addiction Medicine
• American Association for Physician Leadership
• American Society for Adolescent Psychiatry
• American College of Legal Medicine
• American Society of Clinical Psychopharmacology
• International Society for Autism Research

A Phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.

Anita H Clayton, Susan G Kornstein, George I Papakostas, Valerie Arnold, Mark DiBuono, Otto Dueno, George Konis, Elia Acevedo-Diaz, Mustafa Rawaf, Lara Shirikjian, Felipe Suplicy, Drissana Tran, Nick Vatakis, Judith Joseph, Kurian Abraham, Lawrence Ginsberg, Saundra Maass-Robinson, Joel Raskin, Yuki Prescott, Kelly Abernathy, John Hall, Michael Ackermann, William Wargin, Greg Rigdon, Roberta Ball, Elan Cohen, Donald J Garcia Jr, Michael Downing, Beal Essink, Corinna Gamez, Haig Goenjian, Michael Greenbaum, Paul Gross, Willis Holloway, John Mark Joyce, Jelena Kunovac, Mark Lerman, Leon Rosenberg, Rishi Kakar, James Knutson, Gregory Mattingly, Eric Chavez, Andrew Sedillo, Benny Barnhart

Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.

Richard H. Weisler, Lawrence Ginsberg, Patrick Deas, Ben Adeyi, Lenard A. Adler, Bryan Dirks

The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode.

Robert L. Findling, Lawrence D. Ginsberg

Parent-Reported Executive Function Behaviors and Clinician Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in Children Treated with Lisdexamfetamine Dimesylate

Robert L. Findling, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Robert Lasser, Anthony DeLeon, Lawrence D. Ginsberg

Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate.

Alain Katic, Lawrence D. Ginsberg, Rakesh K. Jain, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Cynthia Richards, Robert Lasser, Atilla Turgay, Robert L. Findling

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.

Lawrence Ginsberg, Alain Katic, Ben Adeyi, Bryan Dirks, Thomas Babcock, Robert Lasser, Brian Scheckner, Lenard A. Adler

L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode

Lawrence D. Ginsberg, Alondra Y. Oubre, Yahya A. Daoud

Executive function deficits in children with attention-deficit/ hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study

Atilla Turgay, Lawrence D. Ginsberg, Elias H. Sarkis, Rakesh K. Jain, Ben Adeyi, Joseph Gao, Bryan Dirks, Thomas Babcock, Brian Scheckner, Cynthia Richards, Robert Lasser, Robert L. Findling

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.

Robert L. Findling, Lawrence D. Ginsberg, Rakesh Jain, Joseph Gao

Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder.

Lawrence Ginsberg

Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Thomas J. Spencer, Michael Greenbaum, Lawrence D. Ginsberg, William Rory Murphy

Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.

Frank A. Lopez, Lawrence D. Ginsberg, Valerie Arnold

Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder.

Richard H. Weisler, Amir H Kalali, Andrew J. Cutler, Thomas D Gazda, Lawrence Ginsberg

Efficacy and Safety of Once- versus Twice-Daily Carbamazepine Extended-Release Capsules for the Treatment of Manic Symptoms in Patients with Bipolar I Disorder.

Richard H. Weisler, Amir H Kalali, Andrew J. Cutler, Thomas D Gazda, Lawrence Ginsberg

Bipolar II Disorder: Current and Future Treatment Options

Rif S. El-Mallakh, Richard H. Weisler, Mark H. Townsend, Lawrence Ginsberg

Efficacy and safety of lamotrigine for adults with bipolar disorder in a private practice setting.

Lawrence Ginsberg

Safety of carbamazepine extended-release capsules in bipolar disorder polypharmacy.

Lawrence Ginsberg

Predictors of response to carbamazepine extended-release capsules treatment in bipolar disorder.

Lawrence D Ginsberg

Outcomes and length of treatment with carbamazepine extended-release capsules in bipolar disorder.

Lawrence D Ginsberg

Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult patients.

Lawrence D Ginsberg

Carbamazepine extended-release capsules in the treatment of bipolar disorder.

Lawrence D Ginsberg

A Retrospective Analysis of Changing From Alternative Agents to Carbamazepine Extended-Release Capsules in Bipolar Disorder

Lawrence D Ginsberg

Safety and efficacy of carbamazepine extended-release capsules in patients with bipolar disorder: QD vs BID.

Lawrence D Ginsberg

Carbamazepine extended-release capsules: a retrospective review of its use in children and adolescents.

Lawrence D. Ginsberg

An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD.

David W. Goodman, Lawrence Ginsberg, Richard H. Weisler, Andrew J. Cutler, Paul Hodgkins

Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder.

Arifulla Khan, Lawrence D. Ginsberg, Gregory M. Asnis, Frederick K. Goodwin, Kimberly Davis, Anupama A. Krishnan, Bryan E. Adams

Safety and Tolerability of Lamotrigine for Bipolar Disorder

Charles L. Bowden, Gregory M. Asnis, Lawrence D. Ginsberg, Beth Bentley, Robert A. Leadbetter, Robin White

GW320659 for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children

Joseph DeVeaugh-Geiss, C. Keith Conners, Elias H. Sarkis, Paul Winner, Lawrence D. Ginsberg, J. Michael Hemphill, Antonio Laurenza, Cathleen F. Barrows, Christopher J. Webster, Christopher J. Stotka, Mahnaz Asgharnejad

Enhancement of Attention Processing by Kantroll™ in Healthy Humans: A Pilot Study:

Jon F. DeFrance, Chris Hymel, Michael C. Trachtenberg, Lawrence D. Ginsberg, Forrest C. Schweitzer, Steven Estes, Thomas J H Chen, Eric R. Braverman, John G. Cull, Kenneth Blum

Age-related changes in cognitive ERPs of attenuation.

J.F. DeFrance, S. Sands, F. C. Schweitzer, Lawrence D. Ginsberg, J. C. Sharma

Topographical Analyses of Attention Disorders of Childhood

J.F. DeFrance, S. Smith, F. C. Schweitzer, Lawrence D. Ginsberg, S. Sands

Topographical Analysis of Adolescent Affective Disorders

J.F. DeFrance, Lawrence D. Ginsberg, Bernard A. Rosenberg, Jadgish C. Sharma